Aspire Biopharma Issues Shareholder Letter

ESTERO, FL / ACCESS Newswire / May 28, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today issued the following letter to shareholders from Chief Executive Officer Kraig Higginson. Dear Fellow Shareholders, 2026 is shaping up to be a defining year for Aspire Biopharma Holdings.